Safety outcomes of anti-platelet therapy post coronary artery bypass graft surgery: A systematic review and network meta-analysis of randomized control trials
Restricted accessReview articleFirst published online May, 2024
Safety outcomes of anti-platelet therapy post coronary artery bypass graft surgery: A systematic review and network meta-analysis of randomized control trials
Antiplatelet therapy is used to decrease the risk of graft failure post coronary artery bypass graft surgery. We aimed to compare dual antiplatelet therapy (DAPT) with monotherapy along with a comparison of Aspirin, Ticagrelor, Aspirin+Ticagrelor (A+T) and Aspirin+Clopidogrel (A+C) to determine the major and minor bleeding risk, risk of postoperative myocardial infarction (MI), stroke, and all-cause mortality (ACM).
Methods
Randomized Controlled Trials comparing the four groups were included. Odds ratio (OR) and Absolute Risk (AR) were employed to assess the mean and standard deviation (SD) with 95% confidence intervals (CI). The Bayesian random-effects model was used for statistical analysis. Risk difference and Cochran Q tests were used to calculate rank probability (RP) and heterogeneity, respectively.
Results
We included 10 trials, consisting of 21 arms and 3926 patients. For the risk of major and minor bleed, A + T and Ticagrelor showed the lowest mean value of 0.040 (0.043) and 0.067 (0.073), respectively, and the highest RP of being the safest group. While a direct comparison between DAPT and monotherapy resulted in an OR of 0.57 [0.34, 0.95] for the risk of minor bleed. A + T was found to have the highest RP and the lowest mean value in terms of ACM, MI, and stroke.
Conclusion
No significant difference was found between monotherapy or dual-antiplatelet therapy for the major bleeding risk safety outcome, however DAPT was found to have a significantly higher rate of minor bleeding complications post-CABG. DAPT should be considered as the antiplatelet modality of choice post-CABG.
NagendranJBozsoSJNorrisCM, et al.Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction. J Am Coll Cardiol2018; 71: 819–827. DOI: 10.1016/j.jacc.2017.12.024.
2.
GorkiHHoenickaMRuppP, et al.Similarity of coagulation and inflammation despite different surgical revascularization strategies – a prospective randomized trial. Perfusion2016; 31: 640–647. DOI: 10.1177/0267659116649426.
3.
GaudinoMAntoniadesCBenedettoU, et al.Mechanisms, consequences, and prevention of coronary graft failure. Circulation2017; 136: 1749–1764.
4.
RaivioPMLassilaRKuitunenAH, et al.Increased preoperative thrombin generation and low protein S level associated with unfavorable postoperative hemodynamics after coronary artery bypass grafting. Perfusion2011; 26: 99–106. DOI: 10.1177/0267659110392442.
5.
ManganoDT.Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med2002; 347: 1309–1317. DOI: 10.1056/NEJMoa020798.
6.
ZimmermannNGamsEHohlfeldT. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg2008; 34: 93–108. DOI: 10.1016/j.ejcts.2008.03.023.
7.
ZimmermannNWenkAKimU, et al.Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation2003; 108: 542–547. DOI: 10.1161/01.Cir.0000081770.51929.5a.
8.
EikelboomJWHirshJWeitzJI, et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation2002; 105: 1650–1655. DOI: 10.1161/01.cir.0000013777.21160.07.
9.
SchömigA. Ticagrelor--is there need for a new player in the antiplatelet-therapy field?N Engl J Med2009; 361: 1108–1111. DOI: 10.1056/NEJMe0906549.
10.
WallentinLBeckerRCBudajA, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med2009; 361: 1045–1057. DOI: 10.1056/NEJMoa0904327.
11.
HeldCAsenbladNBassandJP, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol2011; 57: 672–684. DOI: 10.1016/j.jacc.2010.10.029.
12.
LevineGNBatesERBittlJA, et al.2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol2016; 68: 1082–1115. DOI: 10.1016/j.jacc.2016.03.513.
13.
MegaJLSimonT. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet2015; 386: 281–291, DOI: 10.1016/S0140-6736(15)60243-4.
14.
CardosoRKnijnikLWheltonSP, et al.Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: an updated meta-analysis. Int J Cardiol2018; 269: 80–88, DOI: 10.1016/j.ijcard.2018.07.083.
15.
McInnesMDFMoherDThombsBD, et al.Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA2018; 319: 388–396. DOI: 10.1001/jama.2017.19163.
16.
LuGAdesAE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med2004; 23: 3105–3124. DOI: 10.1002/sim.1875.
17.
DiasSWeltonNJCaldwellDM, et al.Checking consistency in mixed treatment comparison meta-analysis. Stat Med2010; 29: 932–944. DOI: 10.1002/sim.3767.
18.
LumleyT. Network meta-analysis for indirect treatment comparisons. Stat Med2002; 21: 2313–2324. DOI: 10.1002/sim.1201.
19.
SalantiGDel GiovaneCChaimaniA, et al.Evaluating the quality of evidence from a network meta-analysis. PLoS One2014; 9: e99682. DOI: 10.1371/journal.pone.0099682.
20.
ThijsVLemmensRFieuwsS. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur Heart J2008; 29: 1086–1092. DOI: 10.1093/eurheartj/ehn106.
21.
Huedo-MedinaTBSánchez-MecaJMarín-MartínezF, et al.Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods2006; 11: 193–206. DOI: 10.1037/1082-989x.11.2.193.
22.
SalantiGAdesAEIoannidisJPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol2011; 64: 163–171. DOI: 10.1016/j.jclinepi.2010.03.016.
23.
KulikAAbreuAMBoronatV, et al.Ticagrelor versus aspirin and vein graft patency after coronary bypass: a randomized trial. J Card Surg2022; 37: 563–570. DOI: 10.1111/jocs.16189.
24.
SawJWongGCMayoJ, et al.Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. Heart2016; 102: 763–769. DOI: 10.1136/heartjnl-2015-308691.
25.
SchunkertHBoeningAvon ScheidtM, et al.Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. Eur Heart J2019; 40: 2432–2440. DOI: 10.1093/eurheartj/ehz185.
26.
SunJCJTeohKHTLamyA, et al.Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting study. Am Heart J2010; 160: 1178–1184. DOI: 10.1016/j.ahj.2010.07.035.
27.
WillemsenLMJanssenPWAPeperJ, et al.Effect of adding ticagrelor to standard aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (POPular CABG): a randomized, double-blind, placebo-controlled trial. Circulation2020; 142: 1799–1807. DOI: 10.1161/circulationaha.120.050749.
28.
GasparovicHPetricevicMKopjarT, et al.Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting. Am J Cardiol2014; 113: 1660–1667. DOI: 10.1016/j.amjcard.2014.02.024.
29.
KulikALe MayMRVoisineP, et al.Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial. Circulation2010; 122: 2680–2687. DOI: 10.1161/circulationaha.110.978007.
30.
MannacioVADi TommasoLAntignanA, et al.Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of coronary arteRY bypaSS occlusion after off-pump procedures) randomised study. Heart2012; 98: 1710–1715. DOI: 10.1136/heartjnl-2012-302449.
31.
MujanovicENurkicMCalukJ, et al.The effect of combined clopidogrel and aspirin therapy after off-pump coronary surgery: a pilot study. Innovations (Phila)2009; 4: 265–268. DOI: 10.1097/IMI.0b013e3181bbc754.
32.
ZhaoQZhuYXuZ, et al.Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA2018; 319: 1677–1686. DOI: 10.1001/jama.2018.3197.
33.
RajahSMNairUReesM, et al.Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. J Thorac Cardiovasc Surg1994; 107: 1146–1153.
34.
ChesebroJH. Effect of dipyridamole and aspirin on vein graft patency after coronary bypass operations. Thromb Res Suppl1990; 12: 5–10. DOI: 10.1016/0049-3848(90)90433-d.
35.
van der MeerJBrutel de la RivièreAvan GilstWH, et al.Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS research group of the interuniversity cardiology institute of the Netherlands: prevention of coronary artery bypass graft occlusion by aspirin, dipyridamole and acenocoumarol/phenprocoumon study. J Am Coll Cardiol1994; 24: 1181–1188. DOI: 10.1016/0735-1097(94)90096-5.
36.
GavaghanTPGebskiVBaronDW. Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery: a placebo-controlled, randomized study. Circulation1991; 83: 1526–1533. DOI: 10.1161/01.cir.83.5.1526.
37.
GaoCRenCLiD, et al.Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. Ann Thorac Surg2009; 88: 59–62. DOI: 10.1016/j.athoracsur.2009.04.024.
38.
RafiqSJohanssonPIKofoedKF, et al.Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trial. Platelets2017; 28: 786–793. DOI: 10.1080/09537104.2017.1280147.
39.
GoldmanSCopelandJMoritzT, et al.Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy: results of a veterans administration cooperative study. Circulation1989; 80: 1190–1197. DOI: 10.1161/01.cir.80.5.1190.
40.
BrownBGCukingnanRADeRouenT, et al.Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery. Circulation1985; 72: 138–146. DOI: 10.1161/01.cir.72.1.138.
41.
GuiterasPAltimirasJArísA, et al.Prevention of aortocoronary vein-graft attrition with low-dose aspirin and triflusal, both associated with dipyridamole: a randomized, double-blind, placebo-controlled trial. Eur Heart J1989; 10: 159–167. DOI: 10.1093/oxfordjournals.eurheartj.a059456.
42.
MeisterWvon SchackyCWeberM, et al.Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a placebo-controlled trial. Br J Clin Pharmacol1984; 17: 703–711. DOI: 10.1111/j.1365-2125.1984.tb02407.x.
43.
TetikSAkKIsbirS, et al.Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clin Appl Thromb Hemost2010; 16: 189–198. DOI: 10.1177/1076029609344980.
44.
GerschutzGPBhattDL.Clopidogrel in Unstable Angina to Prevent Recurrent Events Study. The clopidogrel in unstable angina to prevent recurrent events (CURE) study: to what extent should the results be generalizable?Am Heart J2003; 145: 595–601. DOI: 10.1067/mhj.2003.180.
45.
WellsGAElliottJKellyS, et al.CADTH optimal use reports: dual antiplatelet therapy following percutaneous coronary intervention: clinical and economic impact of standard versus extended duration, Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health, 2019.
46.
SoloKLaviSKabaliC, et al.Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ2019; 367: l5476. DOI: 10.1136/bmj.l5476.
47.
AgarwalNMahmoudANPatelNK, et al.Meta-analysis of aspirin versus dual antiplatelet therapy following coronary artery bypass grafting. Am J Cardiol2018; 121: 32–40. DOI: 10.1016/j.amjcard.2017.09.022.
48.
VermaSGoodmanSGMehtaSR, et al.Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? a meta-analysis of randomized controlled trials. BMC Surg2015; 15: 112. DOI: 10.1186/s12893-015-0096-z.
49.
GuptaSBelley-CoteEPPanchalP, et al.Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. Interact Cardiovasc Thorac Surg2020; 31: 354–363. DOI: 10.1093/icvts/ivaa115.
50.
KrimlyAYanRTYanAT, et al.Use of clopidogrel post-coronary artery bypass surgery in Canadian patients with acute coronary syndromes. Can J Cardiol2011; 27: 711–715. DOI: 10.1016/j.cjca.2011.06.003.
51.
BiancariFBrasciaDOnoratiF, et al.Prediction of severe bleeding after coronary surgery: the WILL-BLEED risk score. Thromb Haemost2017; 117: 445–456. DOI: 10.1160/th16-09-0721.
52.
VuylstekeAPagelCGerrardC, et al.The papworth bleeding risk score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg2011; 39: 924–930. DOI: 10.1016/j.ejcts.2010.10.003.
53.
MariscalcoGGherliRAhmedAB, et al.Validation of the European multicenter study on coronary artery bypass grafting (E-CABG) bleeding severity definition. Ann Thorac Surg2016; 101: 1782–1788. DOI: 10.1016/j.athoracsur.2015.10.028.
54.
GunertemEUrcunSPalaAA, et al.Predictiveness of different preoperative risk assessments for postoperative bleeding after coronary artery bypass grafting surgery. Perfusion2021; 36: 277–284. DOI: 10.1177/0267659120941327.
55.
KleinAACollierTYeatesJ, et al.The ACTA PORT-score for predicting perioperative risk of blood transfusion for adult cardiac surgery. Br J Anaesth2017; 119: 394–401. DOI: 10.1093/bja/aex205.
56.
AlghamdiAADavisABristerS, et al.Development and validation of transfusion risk understanding scoring tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion2006; 46: 1120–1129. DOI: 10.1111/j.1537-2995.2006.00860.x.
57.
RanucciMCastelvecchioSFrigiolaA, et al.Predicting transfusions in cardiac surgery: the easier, the better: the transfusion risk and clinical knowledge score. Vox Sang2009; 96: 324–332. DOI: 10.1111/j.1423-0410.2009.01160.x.
